Browse by author
Lookup NU author(s): Professor Claire Harris, Professor David KavanaghORCiD, Dr Ruyue Sun
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2018 The Authors The complement system is well known for its role in innate immunity and in maintenance of tissue homeostasis, providing a first line of defence against infection and playing a key role in flagging apoptotic cells and debris for disposal. Unfortunately complement also contributes to pathogenesis of a number of diseases; in some cases driving pathology, and in others amplifying or exacerbating the inflammatory and damaging impact of non-complement disease triggers. The role of complement in pathogenesis of an expanding number of diseases has driven industry and academia alike to develop an impressive arsenal of anti-complement drugs which target different proteins and functions of the complement cascade. Evidence from genetic and biochemical analyses, combined with improved identification of complement biomarkers and supportive data from sophisticated animal models of disease, has driven a drug development landscape in which the indications selected for clinical trial cluster in three ‘target’ tissues: the kidney, eye and vasculature. While the disease triggers may differ, complement activation and amplification is a common feature in many diseases which affect these three tissues. An abundance of drugs are in clinical development, some show favourable progression whereas others experience significant challenges. However, these hurdles in themselves drive an ever-evolving portfolio of ‘next-generation’ drugs with improved pharmacokinetic and pharmacodynamics properties. In this review we discuss the indications which are in the drug development ‘spotlight’ and review the relevant indication validation criteria. We present current progress in clinical trials, highlighting successes and difficulties, and look forward to approval of a wide selection of drugs for use in man which give clinicians choice in mechanistic target, modality and route of delivery.
Author(s): Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D
Publication type: Article
Publication status: Published
Journal: Molecular Immunology
Year: 2018
Volume: 102
Pages: 89-119
Print publication date: 01/10/2018
Online publication date: 16/08/2018
Acceptance date: 06/06/2018
Date deposited: 29/08/2018
ISSN (print): 0161-5890
ISSN (electronic): 1872-9142
Publisher: Pergamon Press
URL: https://doi.org/10.1016/j.molimm.2018.06.008
DOI: 10.1016/j.molimm.2018.06.008
Altmetrics provided by Altmetric
